Wu Liping, Pan Jing, Thoroddsen Vala, Wysong Deborah R, Blackman Ronald K, Bulawa Christine E, Gould Alexandra E, Ocain Timothy D, Dick Lawrence R, Errada Patrick, Dorr Patrick K, Parkinson Tanya, Wood Tony, Kornitzer Daniel, Weissman Ziva, Willis Ian M, McGovern Karen
Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts. Pfizer Global Research and Development, Sandwich, United Kingdom.
Eukaryot Cell. 2003 Apr;2(2):256-64. doi: 10.1128/EC.2.2.256-264.2003.
A genetic approach utilizing the yeast Saccharomyces cerevisiae was used to identify the target of antifungal compounds. This analysis led to the identification of small molecule inhibitors of RNA polymerase (Pol) III from Saccharomyces cerevisiae. Three lines of evidence show that UK-118005 inhibits cell growth by targeting RNA Pol III in yeast. First, a dominant mutation in the g domain of Rpo31p, the largest subunit of RNA Pol III, confers resistance to the compound. Second, UK-118005 rapidly inhibits tRNA synthesis in wild-type cells but not in UK-118005 resistant mutants. Third, in biochemical assays, UK-118005 inhibits tRNA gene transcription in vitro by the wild-type but not the mutant Pol III enzyme. By testing analogs of UK-118005 in a template-specific RNA Pol III transcription assay, an inhibitor with significantly higher potency, ML-60218, was identified. Further examination showed that both compounds are broad-spectrum inhibitors, displaying activity against RNA Pol III transcription systems derived from Candida albicans and human cells. The identification of these inhibitors demonstrates that RNA Pol III can be targeted by small synthetic molecules.
利用酿酒酵母的遗传学方法来鉴定抗真菌化合物的作用靶点。该分析导致鉴定出酿酒酵母RNA聚合酶(Pol)III的小分子抑制剂。三条证据表明UK-118005通过靶向酵母中的RNA Pol III来抑制细胞生长。首先,RNA Pol III最大亚基Rpo31p的g结构域中的显性突变赋予对该化合物的抗性。其次,UK-118005可迅速抑制野生型细胞中的tRNA合成,但对UK-118005抗性突变体则无此作用。第三,在生化测定中,UK-118005在体外抑制野生型而非突变型Pol III酶的tRNA基因转录。通过在模板特异性RNA Pol III转录测定中测试UK-118005的类似物,鉴定出一种效力明显更高的抑制剂ML-60218。进一步研究表明,这两种化合物都是广谱抑制剂,对来自白色念珠菌和人类细胞的RNA Pol III转录系统均有活性。这些抑制剂的鉴定表明RNA Pol III可被小分子合成化合物靶向作用。